



PRESS RELEASE

CARMAT is continuing to analyze the first prosthesis, implanted for 74 days

- The results of this analysis are not yet known.
- This analysis is being carried out in accordance with the customary clinical trial monitoring rules, under the supervision of independent monitoring committees.

Paris, March 17, 2014

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, providing an alternative for people suffering from terminal heart failure, today confirms that it is continuing to analyze the data from the first implanted prosthesis, and will continue the clinical trial once it has obtained the results of the data from this first implantation.

The prosthesis, its control console, their respective power supplies and above all the interactions between the weakened organism of a patient with terminal heart failure and the prosthesis are very complex issues. More than 4,000 pieces of data are recorded every second. The detailed analysis is still being carried out, but at the current time there is no single explanation, only hypotheses that will be substantiated or not in the coming weeks by in-house and external experts.

The results of the analyses of the first implantation, like the following implantations, will notably be reviewed by the Data and Safety Monitoring Board (DSMB).

From the Company's point of view, the first implantation was positive, with the patient surviving for 74 days within the framework of a trial where the benchmark for success was 30 days. The approved medical centers are continuing to assess the next patients for the ongoing clinical trial.

As stated in the Company's 2012 Registration document and the press release of March 4, 2014, CARMAT is not planning to publish any interim results, subject to regulatory obligations or specific circumstances.

CARMAT does not accept any responsibility or liability for information released beyond its control.

About CARMAT: the world's most advanced total artificial heart project.

The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT's aim is to be able to provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.

The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

Imitating the natural heart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

Strongly committed, prestigious founders and shareholders: [Truffle Capital](#), a leading European venture capital firm, [EADS](#), the [Fondation Alain Carpentier](#), the [Centre Chirurgical Marie Lannelongue](#), and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

For more information: www.carmatsa.com

•••

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company's objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.

No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the *Document de Référence* registered with *the Autorité des Marchés Financiers* under number R.13-027 on May 30, 2013 and the *Note d'Opération* that was approved with visa no. 11-308 on July 11, 2011, changes in economic conditions, the financial markets or the markets in which Carmat operates. In particular, no guarantee can be given concerning the Company's ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark.

•••

CARMAT
Marcello Conviti - CEO

Patrick Coulombier - COO

Valerie Leroy - Director of Marketing
& Investor Relations
Tel. : +33 139 456450
contact@carmatsas.com

Alize RP
Press relations

Caroline Carmagnol
+33 (0)1 70 22 53 90
caroline@alizerp.com



Name: **CARMAT**
ISIN code: **FR0010907956**
Ticker: **ALCAR**

NewCap
Financial communication
and investor relations

**Dusan Oresansky /
Emmanuel Huynh**
Tel.: +33 144 719494
carmat@newcap.fr